Featured 13F manager
Johnson & Johnson
New Brunswick, NJ 6 processed 13Fs on this site · 2025 Q3–2026 Q2
- $799M
- 15 Positions
- 2026 Q2
- +22.5% QoQ
- Top 5 88.8%
Johnson & Johnson files a Form 13F. The latest book is 2026 Q2 at $799M, up 22.5% QoQ, led by Protagonist Therapeutics, Nanobiotix, and Meiragtx.
Portfolio
top 5 88.8% · top 10 98.4%
- PTGX - Protagonist Therapeutics 37.6%
- NBTX - Nanobiotix 26.6%
- MGTX - Meiragtx 11.2%
- RAPP - Rapport Therapeutics 9.3%
- CTNM - Contineum Therapeutics · CL A 4.1%
- Legend Biotech 2.9%
- CVRX — 2.6%
- Xencor 1.5%
- CBRS - Cerebras Systems · CL A 1.5%
- FATE - Fate Therapeutics 1.1%
- PRCT - Procept Biorobotics 1.0%
- NMRA - Neumora Therapeutics 0.4%
- Other 0.2%
AUM over time
Book
| PTGX - Protagonist Therapeutics | 32.30% | Hold | 2,449,183 | $66.43 | $163M |
| NBTX - Nanobiotix S A | 21.09% | Hold | 5,623,816 | $18.89 | $106M |
| MGTX - MeiraGTx | 10.85% | Hold | 6,641,064 | $8.23 | $55M |
| RAPP - Rapport Therapeutics | 10.52% | Hold | 1,784,517 | $29.70 | $53M |
| CVRX — | 6.57% | Hold | 4,103,430 | $8.07 | $33M |
| Legend Biotech | 5.27% | Hold | 814,586 | $32.61 | $27M |
| CTNM - Contineum Therapeutics · CL A | 4.62% | Hold | 1,979,173 | $11.75 | $23M |
| PRCT - Procept BioRobotics | 2.54% | Hold | 357,939 | $35.69 | $13M |
| Xencor | 1.74% | Hold | 748,062 | $11.73 | $9M |
| ARWR - Arrowhead Pharmaceuticals | 1.70% | Hold | 247,598 | $34.49 | $9M |
| FATE - Fate Therapeutics | 0.85% | Hold | 3,379,064 | $1.26 | $4M |
| NMRA - Neumora Therapeutics | 0.67% | Hold | 1,849,445 | $1.82 | $3M |
| Vor Biopharma | 0.52% | Hold | 53,732 | $48.72 | $3M |
| Rallybio | 0.36% | Hold | 3,636,363 | $0.4990 | $2M |
| LYEL - Lyell Immunopharma | 0.13% | Hold | 41,165 | $16.24 | $669K |
| Nano-X Imaging | 0.12% | Hold | 158,852 | $3.70 | $588K |
| LAB - Standard BioTools | 0.08% | Hold | 311,967 | $1.30 | $406K |
| Adicet Bio | 0.06% | Hold | 364,472 | $0.8102 | $295K |
| BiomX | 0.01% | Hold | 96,866 | $0.5250 | $51K |
| Senseonics | 0.00% | Hold | 54,621 | $0.4358 | $24K |
Filings history
4 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 15 | $799M | +22.5% | 13F-HR | 8/6/2026 | 000090445426000435 |
| 2026 Q1 | 16 | $652M | +17.5% | 13F-HR | 5/13/2026 | 000090445426000280 |
| 2025 Q4 | 17 | $555M | — | RESTATEMENT | 3/18/2026 | 000090445426000192 |
| 2025 Q4 | 17 | $555M | +10.1% | 13F-HR | 2/13/2026 | 000090445426000111 |
| 2025 Q3 | 20 | $504M | — | RESTATEMENT | 3/18/2026 | 000090445426000190 |
| 2025 Q3 | 20 | $504M | — | 13F-HR | 11/13/2025 | 000090445425000587 |
About
Johnson & Johnson
6 processed 13Fs on this site · 2025 Q3–2026 Q2